MAIA Biotechnology, Inc.
NYSE:MAIANYSE
4 announcements
Credibility Score65%
MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer
OverhypedModerate hypeunclear
MAIA reports 88% disease control in Phase 2 NSCLC trial, far above standard therapies.
17 Nov 2026, 13:45 UTC
▼
MAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung Cancer
OverhypedModerate hypeunclear
MAIA reports 90.5% interim disease control in NSCLC trials, with Phase 3 enrollment at 65%.
7 Oct 2026, 12:18 UTC
▼
MAIA Biotechnology Announces Open Market Purchases by CEO and Director
OverhypedModerate hypeunclear
Insider buying signals confidence, but no hard data backs up the biotech’s bold claims.
2 Jun 2026, 13:59 UTC
▼
MAIA Biotechnology, Inc.: Termination of a Material Definitive Agreement
Routineunclear
This filing reveals only that a major contract was ended, with zero context or detail.
14 May 2026, 21:12 UTC
▼